Medicare GLP-1 Bridge Program 2026: How to Get Wegovy for $50 a Month

For years, Medicare beneficiaries watched from the sidelines as GLP-1 medications transformed weight management for commercially insured patients. Medicare Part D explicitly excluded coverage for anti-obesity medications — a policy that dated back to 2003 and affected tens of millions of Americans over 65 who could have benefited from these treatments.

That changed. The Treat and Reduce Obesity Act provisions and subsequent CMS guidance have opened a pathway for Medicare beneficiaries to access GLP-1 medications for weight loss. Here is what you need to know about the current landscape and how to potentially get Wegovy for around $50 per month.

What Changed in Medicare GLP-1 Coverage

Historically, Medicare Part D plans were prohibited from covering drugs prescribed solely for weight loss or cosmetic purposes. This was a statutory exclusion — not a decision made by individual insurance plans, but baked into the law itself.

The shift came through a combination of legislative action and FDA label expansions. When semaglutide (Wegovy) received FDA approval for cardiovascular risk reduction in patients with established cardiovascular disease and obesity or overweight, it opened a critical coverage pathway. A GLP-1 medication prescribed for cardiovascular risk reduction — rather than weight loss alone — falls outside the anti-obesity drug exclusion.

Additionally, recent legislative efforts have pushed toward removing the anti-obesity medication exclusion entirely for Medicare Part D. The 2026 landscape reflects a transitional period where coverage is expanding but not yet universal.

The Bridge Program Concept

The term "bridge program" refers to manufacturer-sponsored patient assistance programs that work in conjunction with Medicare Part D coverage to reduce out-of-pocket costs. Novo Nordisk (the maker of Wegovy) has maintained various savings programs that can bring the patient cost down significantly.

Here is how it typically works:

1. Medicare Part D covers the medication under qualifying diagnoses (cardiovascular risk reduction, type 2 diabetes management)
2. The manufacturer savings card covers most or all of the remaining copay
3. Patient out-of-pocket cost can drop to as low as $0-50 per month during the coverage period

The specific terms of these programs change frequently, so verifying current eligibility with the manufacturer directly is always recommended.

Who Qualifies

To access GLP-1 coverage through Medicare in 2026, patients generally need to meet these criteria:

Medical criteria:

• BMI of 30 or greater, OR BMI of 27 or greater with at least one weight-related comorbidity
• For the cardiovascular indication: established atherosclerotic cardiovascular disease (prior heart attack, stroke, peripheral artery disease) combined with overweight or obesity

Medicare criteria:

• Enrolled in a Medicare Part D plan that covers the specific medication
• Meeting any prior authorization requirements set by the plan
• Having a qualifying diagnosis documented by the prescribing physician

Important distinction: Coverage under the cardiovascular indication is more broadly available than coverage for obesity alone. If you have both obesity and cardiovascular disease, the cardiovascular indication is typically the more reliable pathway to coverage.

Step-by-Step: How to Access the Program

Step 1: Determine Your Eligibility

Review your medical history with your physician. Key questions:

• Do you have documented cardiovascular disease?
• What is your current BMI?
• Do you have weight-related comorbidities (hypertension, dyslipidemia, type 2 diabetes, sleep apnea)?

Step 2: Check Your Part D Formulary

Not all Medicare Part D plans cover Wegovy or other GLP-1 medications for weight-related indications. Contact your plan directly or check their online formulary. Ask specifically about:

• Is semaglutide (Wegovy) on the formulary?
• What tier is it on?
• Are there prior authorization requirements?
• What is the estimated copay at your coverage phase?

Step 3: Get a Prior Authorization

Most Part D plans require prior authorization for GLP-1 medications. Your physician will need to submit documentation showing:

• Medical necessity
• Qualifying diagnosis
• BMI documentation
• Failed attempts at lifestyle modification (diet and exercise)
• Relevant lab work and clinical history

Step 4: Apply for the Manufacturer Savings Program

Once your Part D coverage is confirmed, apply for the Novo Nordisk patient savings program (for Wegovy) or the Eli Lilly savings program (for Zepbound/tirzepatide). These programs can cover the gap between what Medicare pays and what you owe.

Step 5: Use a Specialty Pharmacy

GLP-1 medications are often routed through specialty pharmacies that can navigate the insurance and savings program coordination. Your prescribing clinic or Part D plan can direct you to an in-network specialty pharmacy.

What If You Do Not Have Cardiovascular Disease?

This is where it gets more complicated. If your primary indication is obesity without cardiovascular disease, Medicare Part D coverage remains inconsistent. Some plans have begun covering anti-obesity medications voluntarily, but this is plan-specific and not guaranteed.

Options in this scenario:

Switch to a Part D plan that covers anti-obesity medications during the next open enrollment period. Plan formularies can change annually, and some plans are now including GLP-1 coverage for obesity.

Use the manufacturer's patient assistance program directly. Novo Nordisk and Eli Lilly both have programs for patients who lack insurance coverage. Income-based eligibility applies.

Consider compounded alternatives. During periods of FDA-recognized shortage, compounded semaglutide has been available at significantly lower cost. However, the regulatory and safety landscape around compounded GLP-1 products is evolving rapidly — discuss this with your physician.

Explore clinical trials. Academic medical centers frequently run trials for GLP-1 medications and related treatments. ClinicalTrials.gov is a searchable database of active studies.

The Donut Hole Problem

Even with Part D coverage, Medicare beneficiaries can hit the coverage gap (the "donut hole") where out-of-pocket costs increase. For expensive medications like GLP-1s, this can happen quickly. The Inflation Reduction Act capped annual out-of-pocket Part D spending at $2,000 starting in 2025, which helps significantly — but you still need to plan for reaching that cap, especially early in the year.

Manufacturer savings programs can help offset costs even within the coverage gap, though the specifics depend on the program terms in effect.

What About Ozempic vs. Wegovy for Medicare Patients?

A common strategy: if Wegovy is not covered by a patient's Part D plan, Ozempic (also semaglutide) may be covered under the diabetes indication. Patients with type 2 diabetes and obesity can sometimes access Ozempic more easily than Wegovy through Medicare, with the weight loss benefits being a secondary effect of the diabetes treatment.

This is a conversation to have with your physician. The prescribing indication matters for coverage purposes, and your doctor needs to document appropriately.

The Bottom Line

Medicare coverage for GLP-1 weight loss medications is real but requires navigation. The days of automatic exclusion are ending, but the current landscape is a patchwork of Part D plan formularies, prior authorization requirements, manufacturer programs, and qualifying diagnoses.

The patients who successfully access these medications at $50 per month or less are typically the ones who work with a prescriber who understands the coverage landscape and is willing to do the documentation work required.

At CORAL, we help Medicare patients navigate GLP-1 access. If you are a Medicare beneficiary interested in semaglutide or tirzepatide, [schedule a consultation](/start) and we will evaluate your coverage options together.

Note: Medicare coverage policies, manufacturer savings programs, and formularies change frequently. The information in this article reflects the landscape as of early 2026. Always verify current coverage with your specific Part D plan and the medication manufacturer.